Type 1 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 1 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-17Clinical Trial Update: Liraglutide In Overweight Patients With Type 1 Diabetes [Phase 3]
Phase 3 clinical trial updating liraglutide use in overweight patients with type 1 diabetes has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-16Clinical Trial Update: The Bihormonal iLet Bionic Pancreas Feasibility Study [Phase 2, Phase 3]
Feasibility study results for the bihormonal iLet bionic pancreas in Type 1 Diabetes Mellitus completed phase 2/3.
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes [Phase 1]
Phase 1 clinical trial of single and repeated doses of glucagon in participants with diabetes was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-12Clinical Trial Update: Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling [NA]
A completed clinical trial evaluating selecting insulin analogs for closed-loop glucose control using multiplex pharmacokinetic profiling in…
-
EMA guidance · 2019-12-06EMA update on metformin diabetes medicines
EMA provides an update on metformin-containing diabetes medicines, outlining current assessments and recommendations related to safety and u…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) [Phase 2]
Phase 2 clinical trial update for CHEF study focused on families with Type 1 Diabetes; completed.
-
FDA approval · 2019-11-26FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for TOUJEO (insulin glargine) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy [Phase 3]
Phase 3 trial assessing sotagliflozin as an adjunct to insulin in adults with type 1 diabetes who have inadequate glycemic control; study co…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: CGM Precision and Glycaemic Variability
The study on CGM precision and glycemic variability in Type 1 diabetes has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone [Phase 3]
Phase 3 trial assessing safety of sotagliflozin added to insulin in adults with Type 1 diabetes and inadequate glycemic control; study compl…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant [Phase 1]
Phase 1 trial update evaluating autologous adult stem cells in patients with Type 1 diabetes and successful renal transplant; results posted…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise [NA]
A terminated clinical trial evaluating glucagon to prevent hypoglycemia during mild exercise in individuals with Type 1 Diabetes Mellitus; r…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas [NA]
Feasibility study of the iLet bihormonal bionic pancreas for type 1 diabetes was terminated; results posted in 2019.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN 70/30 — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for HUMULIN 70/30 (insulin human) submitted by Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN N — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for HUMULIN N (insulin human) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG MIX75/25 — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humalog Mix75/25 (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG MIX50/50 KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMALOG MIX50/50 KWIKPEN (insulin lispro) from Eli Lilly.
-
FDA approval · 2019-11-15FDA Approved: NOVOLIN N — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for NOVOLIN N (human insulin) from Novo Nordisk.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humalog KwikPen (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: BASAGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for BASAGLAR KWIKPEN (insulin glargine) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: FIASP — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for FIASP (insulin aspart injection) from Novo Nordisk.
-
FDA approval · 2019-11-15FDA Approved: LEVEMIR — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for LEVEMIR (insulin detemir) by Novo Nordisk, resulting in updated labeling for the product.
-
FDA approval · 2019-11-15FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for insulin lispro from Eli Lilly, updating/expanding its approved use.
-
FDA approval · 2019-11-15FDA Approved: INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 — Supplemental Application (Novo Nordisk Pharma, Inc.)
FDA approved a supplemental application for Insulin Aspart Protamine and Insulin Aspart Mix 70/30 from Novo Nordisk Pharma, Inc.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN R — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humulin R (insulin human) submitted by Eli Lilly and Company.